On March 9, 2026 Caris Life Sciences (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, reported the launch of a novel, proprietary Caris AI Insights signature for pancreatic cancer included in the Caris Molecular Tumor Board Report. The Caris Molecular Tumor Board Report is an innovative tumor profiling report that provides an additional tumor biology resource and is available upon request with no additional tissue sampling required when ordering MI Cancer Seek.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Caris Life Sciences continues to advance precision oncology by integrating multimodal real-world datasets, available with its proprietary CodeAI platform, enabling the creation of Caris AI Insights, an engine that utilizes Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), and clinical data to generate deeper biological understanding and more actionable insights for clinicians and researchers.
By harnessing AI across its comprehensive real-world datasets, comprised of over 550,000 patients, Caris researchers are building next-generation multimodal models that accelerate biomarker discovery, enhance therapeutic decision-making, and support the development of more personalized cancer treatments.
This signature, designed to support first-line treatment selection for patients with pancreatic ductal adenocarcinoma (PDAC), leverages Caris’ WES and WTS to provide biologically informed insights that may help clinicians personalize therapy decisions in one of the deadliest and most treatment-challenging cancers.
FOLFIRINOX and gemcitabine/nab-paclitaxel (gem/nab-p) are the most commonly used first-line regimens for advanced PDAC, yet limited actionable biomarker guidance exists for therapy selection. As a result, treatment selection often relies on clinical factors rather than tumor biology, exposing patients to potentially unnecessary toxicity with limited benefit.
"Caris AI Insights for PDAC represents a meaningful step forward in bringing molecular intelligence to a disease where clinicians have historically had to make difficult treatment decisions with limited biological guidance," said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. "By harnessing the power of WES and WTS, this Caris AI Insights signature identifies complex molecular patterns that may predict differential benefit between standard first-line regimens. This is exactly the type of advancement to improve patient care that our comprehensive platform was built to deliver."
The PDAC signature provides clinicians with risk categorization (standard or high risk) and treatment recommendations between FOLFIRINOX and gem/nab-p, based on molecular patterns associated with differential benefit. The report includes a Kaplan-Meier plot for patients treated with either regimen, matching the predictions to the clinicians’ patients to advise likely responses.
Caris received FDA approval in November 2024 for MI Cancer Seek, a tissue-based assay that is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors.
A future publication is expected this year, highlighting how Caris AI Insights for pancreatic cancer identified a significant subset of patients who may be candidates for treatment de-escalation, as well as those more likely to benefit from a more intensive regimen and those who likely need the more intensive therapy.
(Press release, Caris Life Sciences, MAR 9, 2026, View Source [SID1234663382])